Treatment Refractory MAC Lung Disease clinical trials at University of California Health
2 in progress, 0 open to eligible people
ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
Sorry, not currently recruiting here
This clinical trial is designed to compare the efficacy and safety of Clofazimine Inhalation Suspension versus placebo when added to guideline-based therapy (GBT)
at UC Davis UCSF
Epetraborole in Patients With Treatment-refractory MAC Lung Disease
Sorry, in progress, not accepting new patients
This is a pivotal Phase 2/3, double-blind, placebo-controlled study of epetraborole + OBR (Optimized Background Regimen) versus placebo + OBR in patients with treatment-refractory MAC lung disease. This study will enroll adult patients with treatment-refractory MAC lung disease who meet all eligibility criteria (including clinical, radiographic, and microbiological criteria).
at UCSF
Our lead scientists for Treatment Refractory MAC Lung Disease research studies include Scott Crabtree, MD Mohamed Fayed, MD, FCCP.
Last updated: